Skip to content
DataLookout
Menu

NCT06966141

A Real World Study of Sacituzumab Govitecan

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 4 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date: Aug 12, 2024 to Feb 5, 2025
    • Eligibility criteria expanded, about 14 words
    • Primary completion pushed from Aug 1, 2026 to Dec 1, 2026
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

PFS
Timeframe: Six months after the last patient was enrolled
ORR
Timeframe: Up to approximately 12 weeks

Arms and interventions

Patients received SG

HER2-negative breast cancer patients who received SG in the advanced stage

Sites

1 site in 1 country

  • Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China